Trial Profile

A Randomised Phase II Trial in Early COVID-19, Assessing Use of Camostat by Blocking SARS-CoV-2 Spike Protein-initiated Membrane Fusion.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 15 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camostat mesilate (Primary)
Indications COVID 2019 infections; Respiratory tract infections
Focus Adverse reactions
Acronyms SPIKE-1

Most Recent Events

23 May 2022 Status changed from active, no longer recruiting to discontinued.
12 Oct 2021 Planned End Date changed from 31 Jul 2021 to 31 Dec 2021.
12 Oct 2021 Planned primary completion date changed from 31 Jul 2021 to 31 Dec 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com